Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billion
marketwatch.com
news
2022-06-02 12:00:00

Shares of Repare Therapeutics Inc. rptx jumped 24.5% in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Holding AG ch:rog to develop and commercialize Repare's experimental tumor treatment. The drug, camonsertib, is being tested as a way to treat tumors with specific synthetic-lethal genomic alterations. Roche will pay Repare $125 million upfront; the agreement also includes up to $1.2 billion in potential milestone payments, royalties on global net sales, and $55 million in what Roche called "potential near-term payments.
